Interface-Engineered Nanocarriers for Translational and Patient-Centric Topical Therapy in Psoriasis

Area of Science:

• Colloid and interface science
• Dermatology
• Nanotechnology

Background:

• Psoriasis is a chronic inflammatory skin disease with limited treatment options.
• Conventional topical therapies face challenges like poor skin penetration and systemic toxicity.
• Nanocarrier systems offer potential solutions for enhanced drug delivery in dermatology.

Purpose of the Study:

• To review the role of interface-engineered nanocarriers in topical psoriasis therapy.
• To highlight advancements in nanocarrier design for improved drug solubility, stability, and skin localization.
• To discuss the translational challenges and future directions for nanocarrier-based psoriasis treatments.

Main Methods:

• Review of recent advancements in colloid and interface science for nanocarrier development.
• Analysis of lipid-based nanosystems, including solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and liposomes.
• Integration of preclinical and clinical data on nanocarrier efficacy for psoriasis treatment.

Main Results:

• Interface engineering optimizes nanocarrier drug solubility, stability, and controlled release.
• Lipid-based nanosystems enhance drug accumulation in psoriatic lesions via skin lipid pathways.
• Studies show improved lesion resolution, reduced side effects, and superior safety profiles with nanocarrier delivery.

Conclusions:

• Interface-tailored nanocarriers represent a promising approach for precision topical psoriasis therapy.
• These systems improve drug efficacy, safety, and patient compliance.
• Addressing challenges in scalability, stability, and regulation is key for clinical translation.